A Phase 3 interventional study of L-citrulline and Placebo in Acute Lung Injury, sponsored by Asklepion Pharmaceuticals, LLC. Completed at 29 sites in 4 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2023-02-23.
Sponsored by Asklepion Pharmaceuticals, LLC · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Acute Lung Injury with a site in United States — 17 open to participants now, 19 under way, 1 of them phase 3. Acute Lung Injury · United States.
Among the 112 studies in Acute Lung Injury with a site in United States, this one is the 23rd largest by enrollment of the 88 interventional ones that give a count, is one of 2 that started in 2016, is one of 11 in phase 3, and was the 64th registered.
382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.
Browse Acute Lung Injury studies →17 of the 112 studies in Acute Lung Injury with a site in United States are open now. Recruiting first, the newest first:
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
Prenosis, Inc. · Sites in United States
Ages 18+
Implicit Bioscience · Sites in United States
Ages 18+
HTIC, Inc · Sites in United States
Ages 18–65 · Healthy volunteers
University of Kentucky · Sites in United States
Ages 18–99 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.
This study: Up to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 42 · Phase 3 17 · Phase 4 4
First in 2001; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 189 is above the median of 60 across 227 interventional studies indexed under Acute Lung Injury.
Median enrollment 68 across the 88 interventional studies, 135 across the 22 observational. Of the 79 that completed or were terminated, 40 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 112 have an industry lead sponsor. The 10 most frequent:
Asklepion Pharmaceuticals, LLC is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Asklepion Pharmaceuticals, LLC has 1 study filed under Acute Lung Injury — fewer than ten, so there is no comparison to draw.
5 of the studies in Acute Lung Injury with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07125079University of PennsylvaniaLung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy. | 2026-12-20 |
| NCT07449572HTIC, IncClinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS | 2027-01 |
| NCT06476132National Institute of Allergy and Infectious Diseases (NIAID)Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients | 2027-05-30 |
| NCT04068012Children's Hospital Los AngelesClinical Decision Support Tool in PARDS Pilot Study | 2027-07 |
| NCT05977153The University of Texas Medical Branch, GalvestonCT for Personalized Mechanical Ventilation | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 112 studies in Acute Lung Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether L-citrulline is effective and safe in the prevention of clinical sequelae of Acute Lung Injury in pediatric subjects undergoing surgery for congenital heart defects.
This is a randomized, double-blind, placebo controlled, multicenter study that will compare the efficacy and safety of L-citrulline versus placebo in subjects undergoing surgery for congenital heart defects.
Eligible subjects undergoing repair of a large unrestrictive ventricular septal defect (VSD), a partial or complete atrioventricular septal defect (AVSD), or an ostium primum atrial septal defect (primum ASD) will be eligible for enrollment in this study.
Each enrolled subject will be randomized to receive either L-citrulline or placebo throughout all administrations in the study. Subjects will receive an L-citrulline bolus of 150 mg/kg or placebo at the initiation of cardiopulmonary bypass, the addition of L-citrulline at a concentration of 200 μmol/L or placebo given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L. L-citrulline bolus of 20 mg/kg or placebo 30 minutes after decannulation from cardiopulmonary bypass, followed immediately by a 9 mg/kg/hr continuous L-citrulline infusion or placebo for up to 48 hours.
The study drug or placebo infusion will be discontinued once invasive arterial blood pressure monitoring is discontinued or at 48 hours, whichever comes first. Subjects will be followed until Day 28 or discharge from the hospital, whichever comes first. For subjects discharged prior to Day 28, a final assessment via telephone will be conducted at Day 28.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evidence of pulmonary artery or vein abnormalities on the pre-operative echocardiogram that will not be addressed surgically. Specific abnormalities excluded include the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base; * Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L; * Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass; * 9 mg/kg/hr continuous infusion for up to 48 hours.
Drug: L-citrulline
* Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass; * Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass; * Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass; * 9 mg/kg/hr continuous infusion for up to 48 hours.
Other: Placebo
* Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base; * Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L; * Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass; * 9 mg/kg/hr continuous infusion for up to 48 hours.
* Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass; * Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass; * Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass; * 9 mg/kg/hr continuous infusion for up to 48 hours.
A Composite Variable Consisting of the Longer of Either (1) Length of Time on Mechanical Ventilation or (2) Length of Inotrope Use.
Mechanical ventilation (MV) = invasive or noninvasive MV incl. bilevel (biphasic) positive airway pressure or continuous positive airway pressure. Inotrope use = medications considered within the derivation of total inotrope score (dopamine, dobutamine, milrinone, epinephrine, phenylephrine, norepinephrine). Both measures recorded until earliest of subject hospital discharge or Day 28.
Time frame: 28 Days
Length of Time on Mechanical Ventilation
The same definitions and analyses as described for the primary endpoint will be applied.
Time frame: 28 Days
Length of Time on Positive Pressure Ventilation
The same definitions and analyses as described for the primary endpoint will be applied.
Time frame: 28 Days
Length of Time of Inotrope Use
The same definitions and analyses as described for the primary endpoint will be applied.
Time frame: 28 days
Inotrope Score
Inotrope score is reflective of the pharmacological support required by the cardiovascular system and is a good predictor of mortality and morbidity in patients undergoing bypass surgery. A lower inotrope score represents less pharmacological support and would indicate a lower risk for a poor clinical outcome. Therefore, any treatment effect would be indicated by a lower inotrope score in the citrulline group when compared to the placebo group. In this study, the score was calculated each hour post-operatively from the time of separation from bypass until the completion of study drug. Additionally, the total inotrope score over time until Day 28 or hospital discharge was derived. Inotrope score was calculated using the following formula: Total inotrope score = Dopamine dose (µg/kg/min) + Dobutamine dose (µg/kg/min) + 10 \* Milrinone dose (µg/kg/min) + 100 \* Epinephrine dose (µg/kg/min) + 100 \* Phenylephrine dose (µg/kg/min) + 100 \* Norepinephrine dose (µg/kg/min).
Time frame: Up to 48 hours after separation from CBP
Hemodynamic Improvement: Heart Rate
Heart rate at hours 1, 2, 4, 12, 24 and 48.
Time frame: 2 Days
Hemodynamic Improvement: Systemic Arterial Blood Pressure
Systemic arterial blood pressure at hours 1, 2, 4, 12, 24 and 48.
Time frame: 2 Days
Hemodynamic Improvement: Oxygen Saturation
Oxygen saturation at hours 1, 2, 4, 12, 24 and 48.
Time frame: 2 Days
Hemodynamic Improvement: Central Venous Pressure
Central venous pressure at hours 1, 2, 4, 12, 24 and 48.
Time frame: 2 Days
Thoracotomy Output
The thoracotomy output is defined as the total volume of chest tube drainage recorded in cc prior to discontinuation of chest intubation. The total postoperative duration (in hours) that the chest tube is used will be calculated as the time from the end of the surgery to the time the chest tube is removed. If an additional chest tube is required or reinserted (until discharge from the hospital or at Day 28) the duration that the additional chest tube was used (from time of insertion to time of removal) will be added to the time the original chest tube was used for the total postoperative duration. If a subject did not use any chest tube the duration is set to 0. As a sensitivity analysis, subjects with no use of chest tube will be excluded. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed duration of chest tube drainage will be used.
Time frame: 28 Days
Length of Time of Intubation
The length will be derived as the time in hours from separation from CPB until discontinuation of intubation. Any duration of re-use of intubation will continue to accrue. If a subject did not use any intubation the length is set to 0. As a sensitivity analysis, subjects with no use of intubations will be excluded. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed length of time on intubation will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of time on intubation of 28 days. For the length of time on intubation the same analyses as described for the primary endpoint will be applied.
Time frame: 28 Days
Length of Pediatric Intensive Care Unit (PICU) Stay
The length of PICU stay will be calculated as the total number of days postoperative until discharge from PICU. For subjects who died before discharge from PICU or before Day 28, respectively, the observed length of PICU stay will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of PICU stay of 28 days. For the length of PICU stay the same analyses as described for the primary endpoint will be applied.
Time frame: 28 Days
Length of Time on Vasodilators
Length of time on vasodilators will be measured from first use following separation from bypass, until the subject is discharged from the hospital or at Day 28. The length will be derived as the time in hours from separation from CPB until discontinuation of all vasodilators.
Time frame: 28 Days
Length of Hospitalization
The length of hospitalization will be calculated as the total number of days postoperative until discharge from the hospital. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed length of hospitalization will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of hospitalization of 28 days. The same analyses as described for the primary endpoint will be applied.
Time frame: 28 Days
Patients With Plasma Concentrations of Citrulline
Plasma citrulline concentrations will be assessed in both treatment groups to determine the number of patients who reach the therapeutic sustained target plasma citrulline level of ≥100 μmol/L. Blood collection for assessment of plasma citrulline concentrations will be taken prior to surgery, during surgery, 30 minutes post-decannulation after CPB (prior to bolus and 5 minutes after bolus), at the specified post-operative time points (6h, 12h, 24h, 48h), and at hospital discharge or Day 28, whichever occurs first.
Time frame: 28 Days
Occurrence of Adverse and Serious Adverse Events
Pre-treatment adverse events and treatment adverse events will be analyzed separately. The number of affected subjects will be reported.
Time frame: 28 Days
Number of Patients With Refractory Hypotension
Refractory hypotension is defined as a 20% drop of mean arterial pressure (MAP) below specific age-related criteria for more than 30 minutes. The number of subjects with any refractory hypotension from end of surgery until 48 hours will be compared between groups.
Time frame: 2 Days
| Milestone | L-citrulline | Placebo |
|---|---|---|
| Started | 99 | 90 |
| Completed | 96 | 90 |
| Not completed | 3 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Mechanical ventilation (MV) = invasive or noninvasive MV incl. bilevel (biphasic) positive airway pressure or continuous positive airway pressure. Inotrope use = medications considered within the derivation of total inotrope score (dopamine, dobutamine, milrinone, epinephrine, phenylephrine, norepinephrine). Both measures recorded until earliest of subject hospital discharge or Day 28.
| Minutes | L-citrulline | Placebo |
|---|---|---|
| A Composite Variable Consisting of the Longer of Either (1) Length of Time on Mechanical Ventilation or (2) Length of Inotrope Use. | 3351.1 ± 5230.8 | 3549.6 ± 6069.1 |
The same definitions and analyses as described for the primary endpoint will be applied.
| Minutes | L-citrulline | Placebo |
|---|---|---|
| Length of Time on Mechanical Ventilation | 2398.4 ± 2031.8 | 5236.9 ± 4714.7 |
The same definitions and analyses as described for the primary endpoint will be applied.
| Minutes | L-citrulline | Placebo |
|---|---|---|
| Length of Time on Positive Pressure Ventilation | 2018.7 ± 4918.5 | 1285.6 ± 2354.8 |
The same definitions and analyses as described for the primary endpoint will be applied.
| Minutes | L-citrulline | Placebo |
|---|---|---|
| Length of Time of Inotrope Use | 2726.4 ± 3637.5 | 3167.3 ± 6035.2 |
Inotrope score is reflective of the pharmacological support required by the cardiovascular system and is a good predictor of mortality and morbidity in patients undergoing bypass surgery. A lower inotrope score represents less pharmacological support and would indicate a lower risk for a poor clinical outcome. Therefore, any treatment effect would be indicated by a lower inotrope score in the citrulline group when compared to the placebo group. In this study, the score was calculated each hour post-operatively from the time of separation from bypass until the completion of study drug. Additionally, the total inotrope score over time until Day 28 or hospital discharge was derived. Inotrope score was calculated using the following formula: Total inotrope score = Dopamine dose (µg/kg/min) + Dobutamine dose (µg/kg/min) + 10 \* Milrinone dose (µg/kg/min) + 100 \* Epinephrine dose (µg/kg/min) + 100 \* Phenylephrine dose (µg/kg/min) + 100 \* Norepinephrine dose (µg/kg/min).
| µg/kg/min | L-citrulline | Placebo |
|---|---|---|
| 1 hour after separation from CBP | 1691.6 ± 11420.8 | 583.6 ± 4879.0 |
| 2 hours after separation from CBP | 5076.2 ± 38880.0 | 537.1 ± 4870.3 |
| 3 hours after separation from CBP | 5983.4 ± 39369.2 | 1258.2 ± 11744.0 |
| 4 hours after separation from CBP | 6044.1 ± 39566.9 | 1257.4 ± 11744.1 |
| 5 hours after separation from CBP | 6044.0 ± 39567.0 | 1257.3 ± 11744.1 |
| 6 hours after separation from CBP | 5983.5 ± 39369.2 | 1243.4 ± 11677.9 |
| 7 hours after separation from CBP | 5983.3 ± 39369.2 | 1243.4 ± 11677.9 |
| 8 hours after separation from CBP | 5983.2 ± 2007.7 | 39369.2 ± 13688.2 |
| 9 hours after separation from CBP | 5983.4 ± 39369.2 | 2007.1 ± 13688.3 |
| 10 hours after separation from CBP | 5983.0 ± 39369.3 | 2007.0 ± 13688.4 |
| 11 hours after separation from CBP | 5983.1 ± 39369.2 | 2007.0 ± 13688.4 |
| 12 hours after separation from CBP | 5983.5 ± 39369.2 | 2006.8 ± 13688.4 |
| 13 hours after separation from CBP | 5983.1 ± 39369.2 | 2006.7 ± 13688.4 |
| 14 hours after separation from CBP | 3255.8 ± 16449.2 | 2006.6 ± 13688.4 |
| 15 hours after separation from CBP | 3255.8 ± 16449.2 | 2006.5 ± 13688.4 |
| 16 hours after separation from CBP | 3255.4 ± 16449.2 | 2006.6 ± 13688.4 |
| 17 hours after separation from CBP | 3255.7 ± 16449.2 | 2006.5 ± 13688.4 |
| 18 hours after separation from CBP | 3255.4 ± 16449.2 | 2006.2 ± 13688.5 |
| 19 hours after separation from CBP | 3254.9 ± 16449.3 | 2006.1 ± 13688.5 |
| 20 hours after separation from CBP | 3254.9 ± 16449.3 | 2005.7 ± 13688.5 |
| 21 hours after separation from CBP | 2143.6 ± 12376.3 | 2107.8 ± 13707.6 |
| 22 hours after separation from CBP | 2143.2 ± 12376.3 | 2005.7 ± 13688.5 |
| 23 hours after separation from CBP | 2143.2 ± 12376.3 | 2005.6 ± 13688.6 |
| 24 hours after separation from CBP | 2143.0 ± 12376.4 | 2005.3 ± 13688.6 |
| 25 hours after separation from CBP | 2142.8 ± 12376.4 | 2005.2 ± 13688.6 |
| 26 hours after separation from CBP | 2142.8 ± 12376.4 | 2004.9 ± 13688.7 |
| 27 hours after separation from CBP | 2041.4 ± 2004.9 | 12352.5 ± 13688.7 |
| 28 hours after separation from CBP | 2041.1 ± 12352.5 | 2005.4 ± 13688.6 |
| 29 hours after separation from CBP | 2041.1 ± 12352.5 | 2004.7 ± 13688.7 |
| 30 hours after separation from CBP | 2041.1 ± 12352.5 | 2004.7 ± 13688.7 |
| 31 hours after separation from CBP | 2040.9 ± 12352.6 | 2004.6 ± 13688.7 |
| 32 hours after separation from CBP | 2041.0 ± 12352.5 | 2004.7 ± 13688.7 |
| 33 hours after separation from CBP | 2041.1 ± 12352.5 | 2004.6 ± 13688.7 |
| 34 hours after separation from CBP | 2041.0 ± 12352.5 | 2004.6 ± 13688.7 |
| 35 hours after separation from CBP | 2040.9 ± 12352.5 | 2004.4 ± 13688.7 |
| 36 hours after separation from CBP | 2041.1 ± 12352.5 | 2004.5 ± 13688.7 |
| 37 hours after separation from CBP | 2040.9 ± 12352.5 | 2004.4 ± 13688.7 |
| 38 hours after separation from CBP | 2040.9 ± 12352.6 | 2004.4 ± 13688.7 |
| 39 hours after separation from CBP | 2040.9 ± 12352.6 | 2004.3 ± 13688.7 |
| 40 hours after separation from CBP | 1012.5 ± 7071.8 | 2004.3 ± 13688.8 |
| 41 hours after separation from CBP | 1012.5 ± 7071.8 | 1282.1 ± 8736.4 |
| 42 hours after separation from CBP | 1012.5 ± 7071.8 | 780.0 ± 7378.4 |
| 43 hours after separation from CBP | 1012.4 ± 7071.8 | 779.9 ± 7378.4 |
| 44 hours after separation from CBP | 1012.4 ± 7071.8 | 780.1 ± 7378.4 |
| 45 hours after separation from CBP | 1012.3 ± 7071.8 | 780.0 ± 7378.4 |
| 46 hours after separation from CBP | 1012.1 ± 7071.9 | 780.0 ± 7378.4 |
| 47 hours after separation from CBP | 1012.1 ± 7071.8 | 780.0 ± 7378.4 |
| 48 hours after separation from CBP | 1012.1 ± 7071.9 | 779.8 ± 7378.4 |
Heart rate at hours 1, 2, 4, 12, 24 and 48.
| Beats per minute | L-citrulline | Placebo |
|---|---|---|
| 1 hour | 80.1 ± 67.9 | 83.6 ± 60.1 |
| 2 hours | 111.2 ± 45.7 | 116.0 ± 46.7 |
| 4 hours | 130.4 ± 27.7 | 133.5 ± 20.1 |
| 12 hours | 120.9 ± 22.0 | 161.9 ± 17.6 |
| 24 hours | 122.2 ± 22.2 | 118.3 ± 14.9 |
| 48 hours | 125.9 ± 18.7 | 125.4 ± 21.0 |
Systemic arterial blood pressure at hours 1, 2, 4, 12, 24 and 48.
| Millimeters of mercury | L-citrulline | Placebo |
|---|---|---|
| 1 hour | 18.4 ± 16.2 | 15.3 ± 14.9 |
| 2 hours | 31.7 ± 17.9 | 32.5 ± 18.2 |
| 4 hours | 42.4 ± 12.1 | 42.1 ± 12.3 |
| 12 hours | 39.7 ± 12.1 | 40.7 ± 10.6 |
| 24 hours | 41.0 ± 12.2 | 40.1 ± 10.8 |
| 48 hours | 40.3 ± 15.8 | 42.1 ± 11.6 |
Oxygen saturation at hours 1, 2, 4, 12, 24 and 48.
| Percentage of hemoglobin bound to oxygen | L-citrulline | Placebo |
|---|---|---|
| 1 hour | 97.2 ± 7.9 | 95.7 ± 15.8 |
| 2 hours | 98.6 ± 4.6 | 97.6 ± 10.7 |
| 4 hours | 98.5 ± 2.1 | 98.1 ± 2.7 |
| 12 hours | 97.9 ± 2.4 | 97.6 ± 2.6 |
| 24 hours | 97.1 ± 4.0 | 97.6 ± 2.7 |
| 48 hours | 97.6 ± 2.8 | 97.8 ± 2.6 |
Central venous pressure at hours 1, 2, 4, 12, 24 and 48.
| Millimeters of mercury | L-citrulline | Placebo |
|---|---|---|
| 1 hour | 10.2 ± 20.1 | 12.9 ± 28.0 |
| 72 hours | 10.3 ± 5.6 | 13.2 ± 23.9 |
| 4 hours | 13.1 ± 23.7 | 13.2 ± 27.4 |
| 12 hours | 9.7 ± 4.1 | 9.0 ± 3.6 |
| 24 hours | 10.9 ± 5.4 | 9.8 ± 3.6 |
| 48 hours | 11.8 ± 6.2 | 9.6 ± 8.3 |
The thoracotomy output is defined as the total volume of chest tube drainage recorded in cc prior to discontinuation of chest intubation. The total postoperative duration (in hours) that the chest tube is used will be calculated as the time from the end of the surgery to the time the chest tube is removed. If an additional chest tube is required or reinserted (until discharge from the hospital or at Day 28) the duration that the additional chest tube was used (from time of insertion to time of removal) will be added to the time the original chest tube was used for the total postoperative duration. If a subject did not use any chest tube the duration is set to 0. As a sensitivity analysis, subjects with no use of chest tube will be excluded. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed duration of chest tube drainage will be used.
| Milliliters | L-citrulline | Placebo |
|---|---|---|
| Thoracotomy Output | 206.41 ± 137.26 | 198.94 ± 143.85 |
The length will be derived as the time in hours from separation from CPB until discontinuation of intubation. Any duration of re-use of intubation will continue to accrue. If a subject did not use any intubation the length is set to 0. As a sensitivity analysis, subjects with no use of intubations will be excluded. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed length of time on intubation will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of time on intubation of 28 days. For the length of time on intubation the same analyses as described for the primary endpoint will be applied.
| Minutes | L-citrulline | Placebo |
|---|---|---|
| Length of Time of Intubation | 1600.4 ± 4488.9 | 1303.9 ± 4408.3 |
The length of PICU stay will be calculated as the total number of days postoperative until discharge from PICU. For subjects who died before discharge from PICU or before Day 28, respectively, the observed length of PICU stay will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of PICU stay of 28 days. For the length of PICU stay the same analyses as described for the primary endpoint will be applied.
| Days | L-citrulline | Placebo |
|---|---|---|
| Length of Pediatric Intensive Care Unit (PICU) Stay | 6.3 ± 8.5 | 6.5 ± 9.2 |
Length of time on vasodilators will be measured from first use following separation from bypass, until the subject is discharged from the hospital or at Day 28. The length will be derived as the time in hours from separation from CPB until discontinuation of all vasodilators.
| Minutes | L-citrulline | Placebo |
|---|---|---|
| Length of Time on Vasodilators | 1668.4 ± 5751.6 | 611.3 ± 1212.5 |
The length of hospitalization will be calculated as the total number of days postoperative until discharge from the hospital. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed length of hospitalization will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of hospitalization of 28 days. The same analyses as described for the primary endpoint will be applied.
| Days | L-citrulline | Placebo |
|---|---|---|
| Length of Hospitalization | 7.1 ± 5.1 | 3.9 ± 3.9 |
Plasma citrulline concentrations will be assessed in both treatment groups to determine the number of patients who reach the therapeutic sustained target plasma citrulline level of ≥100 μmol/L. Blood collection for assessment of plasma citrulline concentrations will be taken prior to surgery, during surgery, 30 minutes post-decannulation after CPB (prior to bolus and 5 minutes after bolus), at the specified post-operative time points (6h, 12h, 24h, 48h), and at hospital discharge or Day 28, whichever occurs first.
| umol/L | L-citrulline | Placebo |
|---|---|---|
| Day 0 - Intra-Op | 2179.6 ± 1046.8 | 26.4 ± 9.1 |
| Day 0 - 0 hours (prior to bolus) | 1808.9 ± 12549.4 | 27.6 ± 11.3 |
| Day 0 - 0 hours (post bolus) | 1387.8 ± 4957.5 | 27.8 ± 11.6 |
| Day 0 - 6 hours | 146.6 ± 67.3 | 20.3 ± 10.2 |
| Day 0 - 12 hours | 123.8 ± 41.3 | 18.5 ± 8.4 |
| Day 1 - 24 hours | 102.1 ± 42.6 | 14.9 ± 6.8 |
| Day 2 - 48 hours | 68.2 ± 44.9 | 12.1 ± 5.8 |
| Day 28/ Discharge | 21.9 ± 29.5 | 16.9 ± 6.2 |
Pre-treatment adverse events and treatment adverse events will be analyzed separately. The number of affected subjects will be reported.
| Participants | L-citrulline | Placebo |
|---|---|---|
| Any adverse event | 68 | 62 |
| Pre-treatment adverse events | 19 | 12 |
| Treatment emergent adverse events | 68 | 61 |
| Any serious adverse event | 11 | 6 |
Refractory hypotension is defined as a 20% drop of mean arterial pressure (MAP) below specific age-related criteria for more than 30 minutes. The number of subjects with any refractory hypotension from end of surgery until 48 hours will be compared between groups.
| Participants | L-citrulline | Placebo |
|---|---|---|
| Number of Patients With Refractory Hypotension | 0 | 0 |
Mechanical ventilation (MV) = invasive or noninvasive MV incl. bilevel (biphasic) positive airway pressure or continuous positive airway pressure. Inotrope use = medications considered within the derivation of total inotrope score (dopamine, dobutamine, milrinone, epinephrine, phenylephrine, norepinephrine). Both measures recorded until earliest of subject hospital discharge or Day 28. Note: data are reported for post-hoc analyses based on a modified full analysis set (mFAS) targeting the US population for a 48-hour treatment period. Analysis method used was quartiles based, but followed prescribed statistical analysis plan methods. This is because chosen endpoints did not appear to be valid in the ex-US population due to differences in physician decision making. In the US, extubation occurs as soon as a patient's physical condition permits (only more severely ill children remain on mechanical ventilation); conversely, in ex-US sites, children remain on mechanical ventilation.
| Minutes | L-citrulline | Placebo |
|---|---|---|
| A Composite Variable Consisting of the Longer of Either (1) Length of Time on Mechanical Ventilation or (2) Length of Inotrope Use. | 1484.9 ± 1317.1 | 1730.7 ± 1435.5 |
The same definitions and analyses as described for the primary endpoint will be applied.
| Minutes | L-citrulline | Placebo |
|---|---|---|
| Length of Time on Mechanical Ventilation | 420.2 ± 585.1 | 649.7 ± 786.4 |
The same definitions and analyses as described for the primary endpoint will be applied.
| Minutes | L-citrulline | Placebo |
|---|---|---|
| Length of Time on Positive Pressure Ventilation | 200.9 ± 560.5 | 358.0 ± 758.5 |
The same definitions and analyses as described for the primary endpoint will be applied.
| Minutes | L-citrulline | Placebo |
|---|---|---|
| Length of Time of Inotrope Use | 1428.6 ± 1344.6 | 1653.1 ± 1485.7 |
Inotrope score is reflective of the pharmacological support required by the cardiovascular system and is a good predictor of mortality and morbidity in patients undergoing bypass surgery. A lower inotrope score represents less pharmacological support and would indicate a lower risk for a poor clinical outcome. Therefore, any treatment effect would be indicated by a lower inotrope score in the citrulline group when compared to the placebo group. In this study, the score was calculated each hour post-operatively from the time of separation from bypass until the completion of study drug. Additionally, the total inotrope score over time until Day 28 or hospital discharge was derived. Inotrope score was calculated using the following formula: Total inotrope score = Dopamine dose (µg/kg/min) + Dobutamine dose (µg/kg/min) + 10 \* Milrinone dose (µg/kg/min) + 100 \* Epinephrine dose (µg/kg/min) + 100 \* Phenylephrine dose (µg/kg/min) + 100 \* Norepinephrine dose (µg/kg/min).
| µg/kg/min | L-citrulline | Placebo |
|---|---|---|
| Patients on mechanical ventilation for ≤48 hours (US patients) - 1 hour after separation from CBP | 14.7 ± 43.0 | 17.4 ± 44.8 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 2 hours after separation from CBP | 17.2 ± 98.0 | 13.5 ± 58.9 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 3 hours after separation from CBP | 4.5 ± 4.2 | 4.5 ± 3.3 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 4 hours after separation from CBP | 3.6 ± 2.6 | 4.4 ± 3.2 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 5 hours after separation from CBP | 3.7 ± 2.8 | 4.4 ± 2.9 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 6 hours after separation from CBP | 3.7 ± 2.8 | 4.4 ± 2.9 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 7 hours after separation from CBP | 3.6 ± 2.7 | 4.5 ± 3.3 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 8 hours after separation from CBP | 3.4 ± 2.4 | 4.5 ± 3.9 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 9 hours after separation from CBP | 3.4 ± 2.4 | 4.4 ± 3.5 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 10 hours after separation from CBP | 3.4 ± 2.4 | 4.3 ± 3.2 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 11 hours after separation from CBP | 3.3 ± 2.5 | 4.1 ± 2.9 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 12 hours after separation from CBP | 3.4 ± 3.5 | 4.0 ± 3.2 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 13 hours after separation from CBP | 3.3 ± 2.8 | 3.8 ± 3.2 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 14 hours after separation from CBP | 3.1 ± 2.5 | 3.7 ± 3.5 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 15 hours after separation from CBP | 3.1 ± 2.6 | 3.7 ± 3.4 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 16 hours after separation from CBP | 3.0 ± 2.6 | 3.5 ± 3.2 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 17 hours after separation from CBP | 3.1 ± 2.8 | 3.8 ± 4.1 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 18 hours after separation from CBP | 3.0 ± 2.7 | 3.4 ± 3.2 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 19 hours after separation from CBP | 2.8 ± 2.7 | 3.4 ± 3.5 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 20 hours after separation from CBP | 2.9 ± 3.2 | 3.1 ± 3.4 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 21 hours after separation from CBP | 2.6 ± 2.8 | 3.1 ± 3.8 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 22 hours after separation from CBP | 2.3 ± 2.7 | 2.7 ± 3.2 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 23 hours after separation from CBP | 2.2 ± 3.2 | 2.9 ± 4.5 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 24 hours after separation from CBP | 2.1 ± 3.1 | 2.3 ± 3.3 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 25 hours after separation from CBP | 1.8 ± 2.6 | 2.4 ± 4.0 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 26 hours after separation from CBP | 1.7 ± 2.8 | 1.9 ± 3.0 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 27 hours after separation from CBP | 1.5 ± 2.7 | 1.8 ± 2.9 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 28 hours after separation from CBP | 1.4 ± 2.3 | 2.0 ± 3.5 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 29 hours after separation from CBP | 1.3 ± 2.3 | 1.5 ± 2.8 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 30 hours after separation from CBP | 1.4 ± 2.5 | 1.4 ± 2.4 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 31 hours after separation from CBP | 1.2 ± 2.3 | 1.4 ± 2.4 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 32 hours after separation from CBP | 1.2 ± 2.3 | 1.5 ± 3.3 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 33 hours after separation from CBP | 1.2 ± 2.4 | 1.4 ± 2.7 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 34 hours after separation from CBP | 1.1 ± 2.2 | 1.3 ± 2.5 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 35 hours after separation from CBP | 1.2 ± 2.3 | 1.2 ± 2.4 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 36 hours after separation from CBP | 1.1 ± 2.2 | 1.3 ± 2.7 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 37 hours after separation from CBP | 1.1 ± 2.3 | 1.2 ± 2.3 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 38 hours after separation from CBP | 1.0 ± 2.1 | 1.2 ± 2.3 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 39 hours after separation from CBP | 1.0 ± 2.1 | 1.1 ± 2.1 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 40 hours after separation from CBP | 1.0 ± 2.1 | 1.1 ± 2.1 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 41 hours after separation from CBP | 0.9 ± 2.1 | 1.1 ± 2.1 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 42 hours after separation from CBP | 1.0 ± 2.3 | 1.1 ± 2.1 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 43 hours after separation from CBP | 0.8 ± 1.9 | 1.0 ± 2.1 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 44 hours after separation from CBP | 0.9 ± 2.2 | 1.2 ± 2.9 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 45 hours after separation from CBP | 0.7 ± 2.0 | 1.0 ± 2.0 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 46 hours after separation from CBP | 0.6 ± 1.4 | 1.1 ± 2.3 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 47 hours after separation from CBP | 0.6 ± 1.4 | 1.0 ± 2.3 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 48 hours after separation from CBP | 0.4 ± 1.2 | 0.7 ± 1.5 |
Heart rate will be calculated using the absolute changes from baseline at hours 1, 2, 4, 12, 24 and 48 and will be compared between groups using an ANOVA with a fixed effect for treatment group and baseline level. Summary tables describing descriptive measurements will be generated for absolute values and absolute change from baseline values for all observed time points.
| Beats per minute | L-citrulline | Placebo |
|---|---|---|
| Patients on mechanical ventilation for ≤48 hours (US patients) - 1 hour after surgery start | -43.9 ± 78.6 | -40.6 ± 66.4 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 2 hours after surgery start | -14.1 ± 50.0 | 1.1 ± 43.0 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 4 hours after surgery start | 10.0 ± 27.3 | 18.5 ± 24.9 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 12 hours after surgery start | 1.8 ± 19.6 | 5.4 ± 16.5 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 24 hours after surgery start | 3.1 ± 21.3 | 3.3 ± 20.3 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 48 hours after surgery start | 5.8 ± 21.2 | 7.1 ± 26.6 |
Systemic arterial blood pressure will be calculated using the absolute changes from baseline at hours 1, 2, 4, 12, 24 and 48 and will be compared between groups using an ANOVA with a fixed effect for treatment group and baseline level. Summary tables describing descriptive measurements will be generated for absolute values and absolute change from baseline values for all observed time points.
| Millimeters of mercury | L-citrulline | Placebo |
|---|---|---|
| Patients on mechanical ventilation for ≤48 hours (US patients) - 1 hour after surgery start | -17.9 ± 13.2 | -22.3 ± 17.1 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 2 hours after surgery start | -3.8 ± 19.1 | -4.0 ± 17.8 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 4 hours after surgery start | 7.3 ± 12.5 | 8.9 ± 13.5 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 12 hours after surgery start | 6.6 ± 11.7 | 7.2 ± 13.1 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 24 hours after surgery start | 8.8 ± 12.9 | 8.4 ± 11.4 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 48 hours after surgery start | 6.5 ± 17.9 | 7.6 ± 14.5 |
Oxygen saturation will be calculated using the absolute changes from baseline at hours 1, 2, 4, 12, 24 and 48 and will be compared between groups using an ANOVA with a fixed effect for treatment group and baseline level. Summary tables describing descriptive measurements will be generated for absolute values and absolute change from baseline values for all observed time points.
| Percentage of hemoglobin bound to oxygen | L-citrulline | Placebo |
|---|---|---|
| Patients on mechanical ventilation for ≤48 hours (US patients) - 1 hour after surgery start | 1.3 ± 6.2 | -1.8 ± 18.2 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 2 hours after surgery start | 2.3 ± 9.4 | 1.5 ± 9.0 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 4 hours after surgery start | 1.4 ± 8.8 | 0.7 ± 9.4 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 12 hours after surgery start | 0.8 ± 8.4 | 0.7 ± 8.7 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 24 hours after surgery start | -0.2 ± 9.9 | 0.2 ± 8.4 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 48 hours after surgery start | 0.4 ± 9.6 | 1.1 ± 10.3 |
Central venous pressure will be calculated using the absolute changes from baseline at hours 1, 2, 4, 12, 24 and 48 and will be compared between groups using an ANOVA with a fixed effect for treatment group and baseline level. Summary tables describing descriptive measurements will be generated for absolute values and absolute change from baseline values for all observed time points.
| Millimeters of mercury | L-citrulline | Placebo |
|---|---|---|
| Patients on mechanical ventilation for ≤48 hours (US patients) - 1 hour after treatment | -10.0 ± 48.8 | -6.8 ± 45.0 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 2 hours after treatment | -6.5 ± 47.4 | -5.2 ± 43.8 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 4 hours after treatment | 6.7 ± 36.5 | -5.2 ± 41.7 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 12 hours after treatment | -10.4 ± 58.6 | -7.7 ± 41.1 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 24 hours after treatment | -0.1 ± 11.2 | -8.3 ± 43.9 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - 48 hours after treatment | -5.3 ± 17.3 | 6.2 ± 20.8 |
The thoracotomy output is defined as the total volume of chest tube drainage recorded in cc prior to discontinuation of chest intubation. The total postoperative duration (in hours) that the chest tube is used will be calculated as the time from the end of the surgery to the time the chest tube is removed. If an additional chest tube is required or reinserted (until discharge from the hospital or at Day 28) the duration that the additional chest tube was used (from time of insertion to time of removal) will be added to the time the original chest tube was used for the total postoperative duration. If a subject did not use any chest tube the duration is set to 0. As a sensitivity analysis, subjects with no use of chest tube will be excluded. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed duration of chest tube drainage will be used.
| Milliliters | L-citrulline | Placebo |
|---|---|---|
| Thoracotomy Output | 209.42 ± 141.35 | 194.35 ± 124.41 |
The length will be derived as the time in hours from separation from CPB until discontinuation of intubation. Any duration of re-use of intubation will continue to accrue. If a subject did not use any intubation the length is set to 0. As a sensitivity analysis, subjects with no use of intubations will be excluded. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed length of time on intubation will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of time on intubation of 28 days. For the length of time on intubation the same analyses as described for the primary endpoint will be applied.
| Minutes | L-citrulline | Placebo |
|---|---|---|
| Length of Time of Intubation | 329.9 ± 432.6 | 386.5 ± 556.6 |
The length of PICU stay will be calculated as the total number of days postoperative until discharge from PICU. For subjects who died before discharge from PICU or before Day 28, respectively, the observed length of PICU stay will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of PICU stay of 28 days. For the length of PICU stay the same analyses as described for the primary endpoint will be applied.
| Days | L-citrulline | Placebo |
|---|---|---|
| Length of Pediatric Intensive Care Unit (PICU) Stay | 5.6 ± 9.2 | 7.1 ± 10.7 |
Length of time on vasodilators will be measured from first use following separation from bypass, until the subject is discharged from the hospital or at Day 28. The length will be derived as the time in hours from separation from CPB until discontinuation of all vasodilators.
| Minutes | L-citrulline | Placebo |
|---|---|---|
| Length of Time on Vasodilators | 617.9 ± 910.0 | 624.8 ± 1077.1 |
The length of hospitalization will be calculated as the total number of days postoperative until discharge from the hospital. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed length of hospitalization will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of hospitalization of 28 days. The same analyses as described for the primary endpoint will be applied.
| Days | L-citrulline | Placebo |
|---|---|---|
| Length of Hospitalization | 4.9 ± 2.6 | 4.8 ± 2.5 |
Plasma citrulline concentrations will be assessed in both treatment groups to determine the number of patients who reach the therapeutic sustained target plasma citrulline level of ≥100 μmol/L. Blood collection for assessment of plasma citrulline concentrations will be taken prior to surgery, during surgery, 30 minutes post-decannulation after CPB (prior to bolus and 5 minutes after bolus), at the specified post-operative time points (6h, 12h, 24h, 48h), and at hospital discharge or Day 28, whichever occurs first.
| umol/L | L-citrulline | Placebo |
|---|---|---|
| Patients on mechanical ventilation for ≤48 hours (US patients) - Day 0 - Intra-Op | 2264.6 ± 890.1 | 26.7 ± 9.5 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - Day 0 - 0 hours (prior to bolus) | 2625.4 ± 16391.9 | 25.4 ± 8.8 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - Day 0 - 0 hours (post bolus) | 760.1 ± 369.5 | 25.7 ± 9.0 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - Day 0 - 6 hours | 133.7 ± 39.2 | 18.8 ± 8.6 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - Day 0 - 12 hours | 125.6 ± 32.9 | 17.6 ± 7.4 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - Day 1 - 24 hours | 108.4 ± 43.0 | 14.6 ± 6.6 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - Day 2 - 48 hours | 73.3 ± 49.6 | 12.4 ± 6.8 |
| Patients on mechanical ventilation for ≤48 hours (US patients) - Day 28/ Discharge | 28.5 ± 44.3 | 16.2 ± 6.4 |
Pre-treatment adverse events and treatment adverse events will be analyzed separately. The number affected subjects will be reported.
| Participants | L-citrulline - All Patients Off Mechanical Ventilation in ≤48 Hours | L-citrulline - US Patients Off Mechanical Ventilation in ≤48 Hours | L-citrulline - All Patients Off Mechanical Ventilation in >48 Hours | L-citrulline - US Patients Off Mechanical Ventilation in >48 Hours | Placebo - All Patients Off Mechanical Ventilation in ≤48 Hours | Placebo - US Patients Off Mechanical Ventilation in ≤48 Hours | Placebo - All Patients Off Mechanical Ventilation in >48 Hours | Placebo - US Patients Off Mechanical Ventilation in >48 Hours |
|---|---|---|---|---|---|---|---|---|
| Any adverse event | 48 | 30 | 20 | 10 | 47 | 30 | 15 | 8 |
| Pre-treatment adverse events | 12 | 6 | 7 | 3 | 9 | 6 | 3 | 1 |
| Treatment emergent adverse events | 48 | 30 | 20 | 10 | 46 | 29 | 15 | 8 |
| Any serious adverse event | 4 | 2 | 7 | 4 | 2 | 2 | 4 | 3 |
| Pre-treatment serious adverse events | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 |
| Treatment-emergent serious adverse events | 4 | 2 | 7 | 4 | 2 | 2 | 4 | 3 |
Refractory hypotension is defined as a 20% drop of mean arterial pressure (MAP) below specific age-related criteria for more than 30 minutes. The number of subjects with any refractory hypotension from end of surgery until 48 hours will be compared between groups.
No measurements were reported for this outcome.
Collected over Adverse events were recorded from the time of giving informed consent until the Day 28 telephone follow-up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| L-citrulline - All Patients | 0/99 (0%) | 11/99 (11.1%) | 68/99 (68.7%) |
| Placebo - All Patients | 0/90 (0%) | 6/90 (6.7%) | 61/90 (67.8%) |
| L-citrulline - All Patients on Mechanical Ventilation for ≤48 Hours | 0/76 (0%) | 5/76 (6.6%) | 48/76 (63.2%) |
| L-citrulline - US Patients on Mechanical Ventilation for ≤48 Hours | 0/58 (0%) | 2/58 (3.4%) | 30/58 (51.7%) |
| L-citrulline - All Patients on Mechanical Ventilation for >48 Hours | 0/23 (0%) | 7/23 (30.4%) | 20/23 (87%) |
| L-citrulline - US Patients on Mechanical Ventilation for >48 Hours | 0/13 (0%) | 4/13 (30.8%) | 10/13 (76.9%) |
| Placebo - All Patients on Mechanical Ventilation for ≤48 Hours | 0/71 (0%) | 2/71 (2.8%) | 46/71 (64.8%) |
| Placebo - US Patients on Mechanical Ventilation for ≤48 Hours | 0/54 (0%) | 2/54 (3.7%) | 29/54 (53.7%) |
| Placebo - All Patients on Mechanical Ventilation for >48 Hours | 1/19 (5.3%) | 4/19 (21.1%) | 15/19 (78.9%) |
| Placebo - US Patients on Mechanical Ventilation for >48 Hours | 0/12 (0%) | 3/12 (25%) | 8/12 (66.7%) |
| Event | L-citrulline - All Patients | Placebo - All Patients | L-citrulline - All Patients on Mechanical Ventilation for ≤48 Hours | L-citrulline - US Patients on Mechanical Ventilation for ≤48 Hours | L-citrulline - All Patients on Mechanical Ventilation for >48 Hours | L-citrulline - US Patients on Mechanical Ventilation for >48 Hours | Placebo - All Patients on Mechanical Ventilation for ≤48 Hours | Placebo - US Patients on Mechanical Ventilation for ≤48 Hours | Placebo - All Patients on Mechanical Ventilation for >48 Hours | Placebo - US Patients on Mechanical Ventilation for >48 Hours |
|---|---|---|---|---|---|---|---|---|---|---|
| Atrioventricular blockCardiac disorders | 0/99 | 1/90 | 0/76 | 0/58 | 0/23 | 0/13 | 0/71 | 0/54 | 1/19 | 1/12 |
| Failure to thriveMetabolism and nutrition disorders | 0/99 | 1/90 | 0/76 | 0/58 | 0/23 | 0/13 | 0/71 | 1/54 | 1/19 | 1/12 |
| Respiratory acidosisRespiratory, thoracic and mediastinal disorders | 0/99 | 1/90 | 0/76 | 0/58 | 0/23 | 0/13 | 0/71 | 0/54 | 1/19 | 1/12 |
| Swallow study abnormalInvestigations | 1/99 | 0/90 | 0/76 | 0/58 | 1/23 | 1/13 | 0/71 | 0/54 | 0/19 | 0/12 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 1/99 | 0/90 | 0/76 | 0/58 | 1/23 | 1/13 | 0/71 | 0/54 | 0/19 | 0/12 |
| Respiratory arrestRespiratory, thoracic and mediastinal disorders | 1/99 | 0/90 | 0/76 | 0/58 | 1/23 | 1/13 | 0/71 | 0/54 | 0/19 | 0/12 |
| HypotensionVascular disorders | 1/99 | 0/90 | 0/76 | 0/58 | 1/23 | 1/13 | 0/71 | 0/54 | 0/19 | 0/12 |
| Aortic valve incompetenceCardiac disorders | 0/99 | 1/90 | 0/76 | 0/58 | 0/23 | 0/13 | 0/71 | 0/54 | 1/19 | 0/12 |
| Atrioventricular block completeCardiac disorders | 0/99 | 1/90 | 0/76 | 0/58 | 0/23 | 0/13 | 0/71 | 1/54 | 1/19 | 0/12 |
| Cardiac arrestCardiac disorders | 0/99 | 1/90 | 0/76 | 0/58 | 0/23 | 0/13 | 0/71 | 1/54 | 1/19 | 0/12 |
| Event | L-citrulline - All Patients | Placebo - All Patients | L-citrulline - All Patients on Mechanical Ventilation for ≤48 Hours | L-citrulline - US Patients on Mechanical Ventilation for ≤48 Hours | L-citrulline - All Patients on Mechanical Ventilation for >48 Hours | L-citrulline - US Patients on Mechanical Ventilation for >48 Hours | Placebo - All Patients on Mechanical Ventilation for ≤48 Hours | Placebo - US Patients on Mechanical Ventilation for ≤48 Hours | Placebo - All Patients on Mechanical Ventilation for >48 Hours | Placebo - US Patients on Mechanical Ventilation for >48 Hours |
|---|---|---|---|---|---|---|---|---|---|---|
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 6/99 | 2/90 | 2/76 | 1/58 | 4/23 | 4/13 | 2/71 | 2/54 | 0/19 | 0/12 |
| RestlessnessPsychiatric disorders | 14/99 | 14/90 | 8/76 | 0/58 | 6/23 | 0/13 | 10/71 | 0/54 | 4/19 | 0/12 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 12/99 | 11/90 | 6/76 | 1/58 | 6/23 | 2/13 | 7/71 | 2/54 | 4/19 | 0/12 |
| PainGeneral disorders | 16/99 | 19/90 | 11/76 | 1/58 | 5/23 | 1/13 | 16/71 | 2/54 | 3/19 | 0/12 |
| PyrexiaGeneral disorders | 19/99 | 13/90 | 14/76 | 2/58 | 5/23 | 2/13 | 11/71 | 3/54 | 2/19 | 1/12 |
| ConstipationGastrointestinal disorders | 11/99 | 16/90 | 8/76 | 4/58 | 3/23 | 0/13 | 12/71 | 7/54 | 4/19 | 2/12 |
| HypertensionVascular disorders | 12/99 | 12/90 | 10/76 | 9/58 | 2/23 | 2/13 | 12/71 | 10/54 | 0/19 | 0/12 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 7/99 | 6/90 | 3/76 | 0/58 | 4/23 | 2/13 | 4/71 | 2/54 | 2/19 | 1/12 |
| ChylothoraxRespiratory, thoracic and mediastinal disorders | 5/99 | 1/90 | 1/76 | 1/58 | 4/23 | 1/13 | 1/71 | 1/54 | 0/19 | 1/12 |
| VomitingGastrointestinal disorders | 6/99 | 12/90 | 4/76 | 0/58 | 2/23 | 1/13 | 10/71 | 4/54 | 2/19 | 2/12 |
Data shown for all patients (N=189). Additionally data are shown for patients within the USA only (N=137), a subset of all patients (N=189), because endpoints did not appear valid ex-US due to differences in standard of care. The estimated enrollment period was 11 months. The total trial period for a patient was up to 42 days (up to 2 weeks screening, 2 days treatment, up to 28 days follow-up). The trial end was defined as "last patient out" (LPO).
| Age, Customized(Months) | L-citrulline | Placebo | Total |
|---|---|---|---|
| US Patients off mechanical ventilation in ≤48 hours | 16.6 ± 28.4 | 17.3 ± 29.1 | 16.9 ± 28.6 |
| US Patients off mechanical ventilation in >48 hours | 6.6 ± 6.7 | 9.0 ± 11.9 | 7.8 ± 9.4 |
| All patients | 17.4 ± 26.9 | 19.5 ± 31.6 | 18.4 ± 29.2 |
| Sex: Female, Male(Participants) | L-citrulline | Placebo | Total |
|---|---|---|---|
| USA patients — Female | 24 | 32 | 56 |
| USA patients — Male | 34 | 22 | 56 |
| All patients — Female | 45 | 53 | 98 |
| All patients — Male | 54 | 37 | 91 |
| Ethnicity (NIH/OMB)(Participants) | L-citrulline | Placebo | Total |
|---|---|---|---|
| USA patients — Hispanic or Latino | 5 | 8 | 13 |
| USA patients — Not Hispanic or Latino | 53 | 45 | 98 |
| USA patients — Unknown or Not Reported | 0 | 1 | 1 |
| All patients — Hispanic or Latino | 8 | 12 | 20 |
| All patients — Not Hispanic or Latino | 91 | 77 | 168 |
| All patients — Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(participants) | L-citrulline | Placebo | Total |
|---|---|---|---|
| United States | 66 | 71 | 137 |
| Israel | 19 | 22 | 41 |
| Europe | 5 | 6 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Aug 2016 to primary completion in Jun 2019, 34 months.
Results were first posted in Feb 2023, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Citrulline
Asklepion Pharmaceuticals, LLC